Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
Press releases published on July 18, 2025
Human Appeal USA Mobilizes Relief and Volunteer Event for Texas Flood Victims
GlobeNewswire
·
July 18, 2025
DALLAS, July 18, 2025 (GLOBE NEWSWIRE) -- In the wake of devastating floods across Texas, including persistent overflow from the Guadalupe River, Dallas-based nonprofit Human Appeal USA is taking action to support affected families with both on-the-ground …
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
GlobeNewswire
·
July 18, 2025
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent …
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
GlobeNewswire
·
July 18, 2025
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
July 18, 2025
STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of …
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
July 18, 2025
STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® ( …
Hapbee Reports First-Ever Quarterly Profit in Q2 2025 and Achieves Third Consecutive Quarter of Growth
GlobeNewswire
·
July 18, 2025
VANCOUVER, British Columbia, July 18, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF), a wearable wellness technology company and the pioneer of bio-streaming products, today announced its unaudited financial results for the …
Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast
GlobeNewswire
·
July 18, 2025
New York City, NY, July 18, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of muscle building, performance, and strength enhancement, CrazyBulk has emerged as the name reshaping the conversation around legal supplements. As fitness communities move …
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewswire
·
July 18, 2025
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late …
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire
·
July 18, 2025
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory …
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
GlobeNewswire
·
July 18, 2025
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …
Generation Bio Announces 1-for-10 Reverse Stock Split
GlobeNewswire
·
July 18, 2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 …
Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
·
July 18, 2025
RA'ANANA, Israel, July 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has …
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
GlobeNewswire
·
July 18, 2025
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced …
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
GlobeNewswire
·
July 18, 2025
THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of …
Surgery Partners, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call Details
GlobeNewswire
·
July 18, 2025
BRENTWOOD, Tenn., July 18, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its second quarter 2025 results …
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
GlobeNewswire
·
July 18, 2025
CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA® …
Kraig Biocraft Laboratories Nears Strategic Three-Year Government Collaboration to Expand Recombinant Spider Silk Production
GlobeNewswire
·
July 18, 2025
ANN ARBOR, Mich., July 18, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement …
FOXO TECHNOLOGIES INC. ANNOUNCES INTENTION TO SPIN OFF EPIGENETICS SUBSIDIARY
GlobeNewswire
·
July 18, 2025
WEST PALM BEACH, FLORIDA, July 18, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary that is …
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
GlobeNewswire
·
July 18, 2025
MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its Phase 2/3 GARDian3 …
Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée
GlobeNewswire
·
July 18, 2025
MONTRÉAL, 18 juill. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui que la soumission de drogue nouvelle (SDN) pour CREXONT® a été …